Business Context and Reporting Period
This Form 8-K is a current report filed by Aadi Bioscience, Inc. (formerly Aerpio Pharmaceuticals, Inc.) on September 8, 2021. The filing addresses corporate governance changes and auditor transitions resulting from a reverse acquisition merger with "Old Aadi" (Aadi Bioscience, Inc.) completed on August 26, 2021. The company is an emerging growth company listed on The Nasdaq Stock Market LLC under the symbol AADI.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on non-financial corporate events.
Material Changes Versus Prior Period
- Change in Certifying Accountant: The company dismissed Ernst & Young LLP (EY) as its independent registered public accounting firm. EY served as the auditor prior to the merger. The dismissal was not due to any disagreements regarding accounting principles, financial statement disclosure, or auditing scope. BDO USA, LLP, the auditor for Old Aadi, was engaged as the successor auditor to audit the consolidated financial statements for the year ending December 31, 2021.
- Board of Directors Changes: Emma Reeve was appointed as a Class III director to fill a vacancy created by the merger. She was immediately appointed Chair of the Audit Committee. Consequently, Caley Castelein, M.D., resigned from the Audit Committee effective immediately.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding business operations or market conditions. The primary commentary relates to the rationale for the auditor change, confirming it was a procedural result of the reverse acquisition accounting treatment where Old Aadi's historical statements become the Company's historical statements.
Compensatory Arrangements
Ms. Reeve's appointment includes the following compensation terms:
- Cash Retainer: Base annual retainer of $40,000 as a non-employee director, plus $20,000 as Chair of the Audit Committee.
- Equity Grant: An initial stock option grant with a grant date fair value of $325,000. The option vests monthly (1/36th per month) subject to continued service and vests in full upon a change in control.
- Future Eligibility: Beginning with the 2022 annual meeting, Ms. Reeve will be eligible for equity awards on the same terms as other continuing board members.
Risks and Contingencies
The filing explicitly states there were no disagreements or reportable events between the company and EY during the years ended December 31, 2020 and 2019, or the subsequent period. EY confirmed in a letter dated September 9, 2021, that it agrees with the statements made in the filing regarding its dismissal.
Important Facts for Investor Verification
- Verify the impact of the reverse acquisition on the company's historical financial reporting lineage (Old Aadi's statements now serve as the Company's).
- Confirm the transition of audit responsibilities from EY to BDO USA, LLP for the 2021 fiscal year.
- Note the composition of the new Audit Committee: Emma Reeve (Chair), Dr. Hehenberger, and Mr. Maroun.
- Review the specific vesting schedule and change-in-control provisions for the $325,000 stock option granted to the new director.